SUMO1 Rabbit anti-Human, Rat, Polyclonal, Invitrogen™
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA118267
PA1-18267 detects SUMO1 from human and rat samples. PA1-18267 has been successfully used in immunohistochemistry and Western blot procedures. The PA1-18267 immunogen is a synthetic peptide corresponding to residues A(6) K P S T E D L G D K K E G E Y(21) of human SUMO-1, conjugated to diphtheria toxoid. The sequence is 100% conserved in rat. Reconstitute with 100 μL of distilled water.SUMO1 is an ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment, via an isopeptide bond, to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. SUMO1 is involved, for instance, in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. SUMO1 may also regulate a network of genes involved in palate development. Mutations in the gene can result in non-syndromic orofacial cleft 10.
|whole serum with no preservative|
|Sentrin-1, UBL1, SMT3H3, GMP1, SMT3, Small Ubiquitin Related Modifier-1|
|Immunohistochemistry, Western Blot|
|Synthetic peptide corresponding to residues A(6) K P S T E D L G D K K E G E Y(21) of human SUMO-1.|
|-20° C, Avoid Freeze/Thaw Cycles|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok